GlassScriptPhysician profile
Justina C Workman
NPI 1194361055
$1,210.84
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $633 · 2022: $578.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $391.22 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $185.46 | 2021-2022 | |
| Kaleo, INC. | $185.28 | 2021-2022 | |
| Genzyme Corporation | $90.46 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $82.71 | 2021-2022 | |
| Optinose US, INC. | $67.26 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $43.22 | 2022 | |
| Pfizer INC. | $36.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.96 | 2021 | |
| Incyte Corporation | $22.95 | 2021 | |
| Octapharma USA, INC. | $19.82 | 2022 | |
| Uswm, LLC | $18.00 | 2021 | |
| Amgen INC. | $16.70 | 2021 | |
| Alk-Abello, INC | $15.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.99 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justina Workman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.